The overall survival after dextran-conjugated drug treatment was greater than that of free drug treatment (Figure 5B), and the use of DEX-TP resulted in pronounced pancreas desmoplasia reduction, as suggested by the decreased Ki67 signature, wherein the proliferation of cancer cells was specifically hindered, as suggested by the decreased EpCAM signature (Figure 5C, 5D and 5E). This evidence concerns the gene MKI67 and cancer.